JP2016521683A - 過敏性腸症候群の診断を予測するための経路特異的なアッセイ - Google Patents

過敏性腸症候群の診断を予測するための経路特異的なアッセイ Download PDF

Info

Publication number
JP2016521683A
JP2016521683A JP2016514523A JP2016514523A JP2016521683A JP 2016521683 A JP2016521683 A JP 2016521683A JP 2016514523 A JP2016514523 A JP 2016514523A JP 2016514523 A JP2016514523 A JP 2016514523A JP 2016521683 A JP2016521683 A JP 2016521683A
Authority
JP
Japan
Prior art keywords
antibody
acid
group
compound
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016514523A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016521683A5 (https=
Inventor
ファビヨラ セルヴァラジ，
ファビヨラ セルヴァラジ，
フレッド プリンセン，
フレッド プリンセン，
シャラット シン，
シャラット シン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec SA filed Critical Nestec SA
Publication of JP2016521683A publication Critical patent/JP2016521683A/ja
Publication of JP2016521683A5 publication Critical patent/JP2016521683A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Quinoline Compounds (AREA)
JP2016514523A 2013-05-24 2014-05-22 過敏性腸症候群の診断を予測するための経路特異的なアッセイ Pending JP2016521683A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361827506P 2013-05-24 2013-05-24
US61/827,506 2013-05-24
PCT/IB2014/061634 WO2014188377A2 (en) 2013-05-24 2014-05-22 Pathway specific assays for predicting irritable bowel syndrome diagnosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019075081A Division JP2019151637A (ja) 2013-05-24 2019-04-10 過敏性腸症候群の診断を予測するための経路特異的なアッセイ

Publications (2)

Publication Number Publication Date
JP2016521683A true JP2016521683A (ja) 2016-07-25
JP2016521683A5 JP2016521683A5 (https=) 2017-06-29

Family

ID=50884973

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016514523A Pending JP2016521683A (ja) 2013-05-24 2014-05-22 過敏性腸症候群の診断を予測するための経路特異的なアッセイ
JP2016514524A Pending JP2016520199A (ja) 2013-05-24 2014-05-22 過敏性腸症候群を診断するための経路特異的マーカー
JP2019075081A Pending JP2019151637A (ja) 2013-05-24 2019-04-10 過敏性腸症候群の診断を予測するための経路特異的なアッセイ
JP2019104805A Pending JP2019194600A (ja) 2013-05-24 2019-06-04 過敏性腸症候群を診断するための経路特異的マーカー

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2016514524A Pending JP2016520199A (ja) 2013-05-24 2014-05-22 過敏性腸症候群を診断するための経路特異的マーカー
JP2019075081A Pending JP2019151637A (ja) 2013-05-24 2019-04-10 過敏性腸症候群の診断を予測するための経路特異的なアッセイ
JP2019104805A Pending JP2019194600A (ja) 2013-05-24 2019-06-04 過敏性腸症候群を診断するための経路特異的マーカー

Country Status (14)

Country Link
US (5) US9891235B2 (https=)
EP (2) EP3004892B1 (https=)
JP (4) JP2016521683A (https=)
KR (2) KR20160013163A (https=)
CN (2) CN105579852B (https=)
AU (3) AU2014269961A1 (https=)
BR (2) BR112015029320A8 (https=)
CA (2) CA2912993A1 (https=)
HK (1) HK1223361A1 (https=)
IL (2) IL242595B (https=)
MX (1) MX367046B (https=)
RU (2) RU2015155590A (https=)
SG (2) SG11201509371XA (https=)
WO (2) WO2014188378A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019151637A (ja) * 2013-05-24 2019-09-12 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 過敏性腸症候群の診断を予測するための経路特異的なアッセイ

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6495256B2 (ja) 2013-06-21 2019-04-03 オンデック ピーティーワイ リミテッド 免疫療法組成物及びその使用
AU2015257589A1 (en) * 2014-05-09 2016-11-24 Nogra Pharma Limited Methods for treating inflammatory bowel disease
TWI688571B (zh) 2014-11-19 2020-03-21 英商Ｎｚｐ英國有限公司 化合物（四）
US10131688B2 (en) 2014-11-19 2018-11-20 NZP UK Limited 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal FXR modulators
JP2018501202A (ja) 2014-11-19 2018-01-18 ネステク ソシエテ アノニム セロトニン、トリプトファン、及びキヌレニンの代謝産物に対する抗体及びその使用
KR102526631B1 (ko) 2014-11-19 2023-04-27 엔제트피 유케이 리미티드 스테로이드 fxr 조절인자를 제조하기 위한 중간체로서의 6-알킬-7-하이드록시-4-엔-3-온 스테로이드
US10538550B2 (en) 2014-11-19 2020-01-21 NZP UK Limited 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal FXR modulators
HK1244881A1 (zh) * 2014-12-02 2018-08-17 Société des Produits Nestlé S.A. 建立维多珠单坑给药方案以治疗患有易激惹肠病的患者的方法
CN105987995A (zh) * 2015-02-04 2016-10-05 东莞博捷生物科技有限公司 一种检测人抗酿酒酵母IgG类抗体的酶联免疫试剂盒
CN105987996A (zh) * 2015-02-09 2016-10-05 东莞博捷生物科技有限公司 一种检测人抗酿酒酵母IgA类抗体的酶联免疫试剂盒
CN105061305A (zh) * 2015-08-31 2015-11-18 河南师范大学 一步合成3-甲基-2-吡啶甲酸甲酯的方法
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
CN106399344B (zh) * 2016-06-01 2021-01-01 上海领潮生物新材料有限公司 一种vin-cdtb融合蛋白的制备方法
WO2018011691A1 (en) * 2016-07-12 2018-01-18 Nestec S.A. Competitive immunoassay methods
CN106188191A (zh) * 2016-07-13 2016-12-07 西安电子科技大学 基于gsh响应的诊治一体化有机分子探针及其制备方法
US11959125B2 (en) 2016-09-15 2024-04-16 Sun Genomics, Inc. Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample
US10428370B2 (en) 2016-09-15 2019-10-01 Sun Genomics, Inc. Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample
EP3512946A4 (en) * 2016-09-15 2020-04-08 Sun Genomics Inc. UNIVERSAL METHOD FOR EXTRACTING NUCLEIC ACID MOLECULES FROM A DIVERSE POPULATION OF ONE OR MORE TYPES OF MICROBES IN A SAMPLE
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
US11426566B2 (en) 2016-12-14 2022-08-30 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a TLR modulator
US20200253506A1 (en) 2016-12-14 2020-08-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
CN117045784A (zh) 2016-12-14 2023-11-14 比奥拉治疗股份有限公司 使用利用可摄入装置释放的il-12/il-23抑制剂治疗胃肠道疾病
JP2020502126A (ja) 2016-12-14 2020-01-23 プロジェニティ， インコーポレイテッド 消化管疾病のｊａｋ阻害薬による治療
WO2018112237A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
EP3554541B1 (en) 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
CA3047302C (en) * 2016-12-14 2024-01-02 Tracy WARREN System and methods for developing and using a microbiome-based action component for patient health
JP2020513280A (ja) 2016-12-14 2020-05-14 プロジェニティ， インコーポレイテッド 消化管疾病の免疫抑制剤による治療
US11978543B2 (en) 2016-12-14 2024-05-07 Astarte Medical Partners Inc. System and methods for developing and using a microbiome-based action component
WO2018112235A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
CA3046093A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
CN110430801B (zh) 2016-12-14 2024-04-30 比奥拉治疗股份有限公司 使用tnf抑制剂治疗胃肠道疾病
WO2018183941A2 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with live biotherapeutics
WO2018183929A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2018183932A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
CA3054156A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
CA3054159A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
US20200306516A1 (en) 2017-08-14 2020-10-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
EP3750168B1 (en) * 2018-02-09 2025-11-19 Metabolomic Diagnostics Limited A system and method of generating a model to detect, or predict the risk of, an outcome
EP3770606A4 (en) * 2018-03-19 2021-12-29 FUJIFILM Wako Pure Chemical Corporation Method for judging psychiatric disorder
EP3785033B1 (en) * 2018-04-24 2025-12-10 Universiteit Gent Intestinal biomarkers for intestinal health of poultry
AU2019278927A1 (en) 2018-06-01 2020-12-24 Bt Bidco, Inc. Devices and systems for gastrointestinal microbiome detection and manipulation
CA3101541A1 (en) * 2018-06-07 2019-12-12 4D Pharma Plc Method for stratifying ibs patients
CN110607335B (zh) * 2018-06-14 2021-08-03 中国科学院微生物研究所 一种烟酰胺腺嘌呤二核苷酸类化合物生物合成方法
CN109324132A (zh) * 2018-10-31 2019-02-12 杭州佰辰医学检验所有限公司 高通量检测色氨酸及其代谢产物的试剂盒及其应用
US11488699B1 (en) 2018-12-09 2022-11-01 Cerner Innovation, Inc. Microbiota activity sensor and decision support tool
US11842795B1 (en) * 2018-12-17 2023-12-12 Cerner Innovation, Inc. Irritable bowel syndrome diagnostic sensor and decision support tool
FR3094492A1 (fr) * 2019-04-01 2020-10-02 Polyneuros Procédé de détection ou de suivi de l’évolution d’une maladie chronique dégénérative par dosage immunologique
WO2020201458A1 (en) * 2019-04-03 2020-10-08 4D Pharma Cork Limited Methods of diagnosing disease
JPWO2020213732A1 (ja) * 2019-04-18 2021-04-30 株式会社サイキンソー 過敏性腸症候群の検査方法
US11884958B2 (en) * 2019-04-30 2024-01-30 Mayo Foundation For Medical Education And Research Assessing and treating functional gastrointestinal disorders
AU2020275413A1 (en) 2019-05-14 2021-12-23 Cedars-Sinai Medical Center TL1A patient selection methods, systems, and devices
WO2020232262A1 (en) * 2019-05-16 2020-11-19 Procisedx Inc. Assay detection methods for vcam-1 and calprotectin
CN111351870A (zh) * 2019-12-03 2020-06-30 康美华大基因技术有限公司 一种肠易激综合征血清代谢标记物组合及其诊断试剂盒
EP4085256B1 (en) 2020-01-27 2024-01-24 Immundiagnostik AG Test and in vitro diagnosis of irritable bowel syndrome
WO2021152586A1 (en) * 2020-01-30 2021-08-05 Yeda Research And Development Co. Ltd. Methods of analyzing microbiome, immunoglobulin profile and physiological state
EP3913371A1 (en) 2020-05-18 2021-11-24 Neuroimmun GmbH Method and kit for diagnosting irritable bowel syndrome and for its relief through dietary interventions
KR102478205B1 (ko) * 2020-09-24 2022-12-15 경희대학교 산학협력단 크론병 환자에서 상부위장관 침범 진단을 위한 정보 제공 방법
CN114755313B (zh) * 2021-01-08 2024-08-30 复旦大学附属华山医院 包含尿液nad+代谢物的急性肾损伤标志物
CN115724779B (zh) * 2021-09-01 2024-03-29 四川大学 酰胺烷二硫化合物、其制备方法和用途
EP4452939A4 (en) * 2021-12-24 2025-12-10 Kuleon Llc SEROTONINERGIC COMPOUNDS, POLYPODS, AND PROMEDICINAL PRODIGITS OF SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS
WO2023180899A1 (en) * 2022-03-21 2023-09-28 Swain Manish Kumar Device and method for detecting diarrhea
CN116381222A (zh) * 2023-03-23 2023-07-04 北京巴瑞医疗器械有限公司 一种血清素发光免疫检测方法及血清素检测试剂盒
CN116990498B (zh) * 2023-09-28 2024-08-09 山东大学齐鲁医院 血浆色氨酸代谢物在儿童偏头痛诊断中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004527562A (ja) * 2001-04-30 2004-09-09 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング ニコチン性アセチルコリンレセプターリガンドおよび／またはセロトニン作動性リガンドとしての６Ｈ−オキサゾロ［４，５−ｅ］インドール誘導体
JP2012531593A (ja) * 2009-06-25 2012-12-10 ネステク ソシエテ アノニム 過敏性腸症候群の診断方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6218129B1 (en) * 1998-05-15 2001-04-17 Prometheus Laboratories, Inc. Inflammatory bowel disease first step assay system
US6406862B1 (en) 1998-10-06 2002-06-18 The United States Of America As Represented By The Secretary Of The Army Dip-stick assay for C-reactive protein
WO2001044274A1 (en) * 1999-12-15 2001-06-21 Cubist Pharmaceuticals, Inc. Lipopeptides as antibacterial agents
US6838250B2 (en) 2000-03-31 2005-01-04 Ortho-Clinical Diagnostics, Inc. Immunoassay for C-reactive protein
WO2005041896A2 (en) 2003-11-03 2005-05-12 Duke University Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction or stroke
US20060154276A1 (en) * 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US20060019410A1 (en) 2004-07-21 2006-01-26 Qualyst, Inc. Apparatus, kits and methods for evaluating binding interactions, for detecting and quantifying binding molecules, and for sample preparation
WO2007000046A1 (en) * 2005-06-27 2007-01-04 Holburn Biomedical Corporation Methods for diagnosing functional bowel disease
US7873479B2 (en) 2005-12-01 2011-01-18 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US20100094560A1 (en) 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20080085524A1 (en) 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US8278057B2 (en) 2007-09-14 2012-10-02 Nestec S.A. Addressable antibody arrays and methods of use
WO2010120814A1 (en) 2009-04-14 2010-10-21 Prometheus Laboratories Inc. Inflammatory bowel disease prognostics
US20120171672A1 (en) 2009-04-14 2012-07-05 Prometheus Laboratories Inc. Inflammatory bowel disease prognostics
PH12012500850A1 (en) * 2009-10-30 2013-01-07 Prometheus Laboratories Inc Methods for diagnosing irritable bowel syndrome
CA2781654A1 (en) * 2009-11-25 2011-06-03 Hua Gong Novel genomic biomarkers for irritable bowel syndrome diagnosis
US8445215B1 (en) * 2010-07-23 2013-05-21 Nestec S.A. Assays and methods for the detection of Crohn's disease
WO2012158831A1 (en) * 2011-05-16 2012-11-22 Prometheus Laboratories Inc. Performance of a biomarker panel for irritable bowel syndrome
JP2015502740A (ja) * 2011-10-21 2015-01-29 ネステク ソシエテ アノニム 炎症性腸疾患の診断を改善するための方法
MX360479B (es) 2012-10-05 2018-11-05 Nestec Sa Anticuerpos contra microbioma, factores de estres y marcadores de mastocitos como marcadores de diagnostico para ibs.
JP2016521683A (ja) 2013-05-24 2016-07-25 ネステク ソシエテ アノニム 過敏性腸症候群の診断を予測するための経路特異的なアッセイ
DK3078744T3 (da) * 2013-12-04 2020-09-28 Chugai Pharmaceutical Co Ltd Antigen-bindende molekyler, antigen-bindingsaktiviteten af hvilke varierer i henhold til koncentrationen af forbindelser, og biblioteker af molekylerne

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004527562A (ja) * 2001-04-30 2004-09-09 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング ニコチン性アセチルコリンレセプターリガンドおよび／またはセロトニン作動性リガンドとしての６Ｈ−オキサゾロ［４，５−ｅ］インドール誘導体
JP2012531593A (ja) * 2009-06-25 2012-12-10 ネステク ソシエテ アノニム 過敏性腸症候群の診断方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MAKOSZA, TETRAHEDRON, vol. V51 N26, JPN5016005979, 1 January 1995 (1995-01-01), NL, pages 7263 - 7276, ISSN: 0003754805 *
MIKAELA I NICHKOVA, ANALYTICAL AND BIOANALYTICAL CHEMISTRY, vol. V402 N4, JPN5016005978, 10 December 2011 (2011-12-10), DE, pages 1593 - 1600, ISSN: 0003754803 *
TODOROKI K, ANALYTICA CHIMICA ACTA, vol. V555 N1, JPN5016005980, 5 January 2006 (2006-01-05), NL, pages 14 - 19, ISSN: 0003754804 *
YAMAGISHI, Y. ET AL.: "Ribosomal Synthesis of Cyclic Peptides with a Fluorogenic Oxidative Coupling Reaction", CHEMBIOCHEM, vol. 10(9), JPN6018008535, 2009, pages 1469 - 1472, ISSN: 0004084233 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019151637A (ja) * 2013-05-24 2019-09-12 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 過敏性腸症候群の診断を予測するための経路特異的なアッセイ

Also Published As

Publication number Publication date
WO2014188377A3 (en) 2015-03-05
MX367046B (es) 2019-08-02
US10338083B2 (en) 2019-07-02
US20180136233A1 (en) 2018-05-17
US20160139148A1 (en) 2016-05-19
US20180321259A1 (en) 2018-11-08
HK1223361A1 (zh) 2017-07-28
SG11201509370UA (en) 2015-12-30
US9891235B2 (en) 2018-02-13
CN105579852A (zh) 2016-05-11
BR112015029320A2 (pt) 2017-07-25
RU2015155590A (ru) 2017-06-29
IL242597B (en) 2019-02-28
EP3004892B1 (en) 2018-10-10
US9739786B2 (en) 2017-08-22
WO2014188378A1 (en) 2014-11-27
CA2913108A1 (en) 2014-11-27
SG11201509371XA (en) 2015-12-30
HK1223416A1 (en) 2017-07-28
RU2015155552A (ru) 2017-06-27
US10036759B2 (en) 2018-07-31
IL242595B (en) 2019-01-31
CN105392780A (zh) 2016-03-09
JP2016520199A (ja) 2016-07-11
US20170307637A1 (en) 2017-10-26
WO2014188377A2 (en) 2014-11-27
CN105579852B (zh) 2017-12-01
JP2019194600A (ja) 2019-11-07
BR112015029318A2 (pt) 2017-07-25
AU2014269960B2 (en) 2018-05-10
KR20160013163A (ko) 2016-02-03
EP3004892A1 (en) 2016-04-13
US20160130279A1 (en) 2016-05-12
JP2019151637A (ja) 2019-09-12
AU2014269960A1 (en) 2015-11-26
AU2014269961A1 (en) 2015-11-26
KR20160010621A (ko) 2016-01-27
BR112015029320A8 (pt) 2023-01-03
CA2912993A1 (en) 2014-11-27
EP3004068A2 (en) 2016-04-13
AU2018214104A1 (en) 2018-08-30

Similar Documents

Publication Publication Date Title
JP2019151637A (ja) 過敏性腸症候群の診断を予測するための経路特異的なアッセイ
US20170240652A1 (en) Antibodies against serotonin, tryptophan and kynurenine metabolites and uses thereof
JP6971927B2 (ja) リスペリドンハプテンへの抗体及びその使用
JP5941615B2 (ja) ヒトｃｘｃｌ１タンパク質の免疫学的測定方法
US20230417779A1 (en) Pregabalin Immunoassays
WO2010072384A1 (en) ANTI-IDIOTYPE ANTIBODY AGAINST AN ANTIBODY AGAINST THE AMYLOID β PEPTIDE
JP2013502580A (ja) イマチニブ免疫アッセイ
US20220146501A1 (en) Assay methods for the detection of human serum albumin, vitamin d, c-reactive protein, and anti-transglutaminase autoantibody
CA2977759A1 (en) Immunological measurement method for l-fabp and measurement reagent used in said method
WO2018011691A1 (en) Competitive immunoassay methods
JP2022532381A (ja) Ｖｃａｍ－１及びカルプロテクチンのための分析検出方法
JP2023099089A (ja) 干渉抑制薬物動態イムノアッセイ
JP2022540764A (ja) 抗ＴＮＦα生物製剤および抗薬剤抗体の検出
Cernoch et al. Production and analytical characterization of neopterin immunoreagents for biosensor developments
WO2011145664A1 (ja) 含硫黄アミノ酸誘導体
WO2012077643A1 (ja) ｃｏｆｉｌｉｎ１タンパク質の免疫学的測定方法
EP2454260A1 (en) Immunodetection and quantification of pyrazolopyrimidine sedatives
JP2020186175A (ja) 免疫グロブリンａに結合しているペリオスチン並びに免疫グロブリンａに結合しているペリオスチンに結合する抗体、ペリオスチンの測定方法、ペリオスチンの測定試薬及びペリオスチン測定の正確性の改善方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170519

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180313

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180813

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190410

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20190410

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190423

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20190507

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20190614

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20190726

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20190730

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20191126

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20200225

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200414

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20200623

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20200721

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20200721